I just saw your customer split for your CR O business, which was around 38% for Big Pharma and 62% for Biotech. So, I just wanted to ask a question around the biotech funding environment. I know you give these numbers sort of annually, but where do you see sort of the funding environment shaping up in terms of the customers or in acquiring newer customers? So, are you moving towards Big Pharma? I want to understand the scenario from your end.
Questions across 1 call
Divyaxa Agnihotri
HDFC Securities